Monitor trading volume and price stability when shares begin trading post-split on April 24. The move addresses a listing deficiency but does not improve fundamentals; watch for future financing risks given the company's small market cap ($65M) and going concern disclosure mentioned in the filing.
Price Chart
Executive Summary
Cue Biopharma implemented a 1-for-30 reverse stock split effective April 23, 2026, to comply with Nasdaq's minimum bid price listing requirement. The stock will begin trading on a post-split basis on April 24, 2026, under the same ticker CUE with a new CUSIP.
Key Facts
- Cue Biopharma executed a 1-for-30 reverse stock split effective April 23, 2026.
- The reverse stock split was implemented to regain compliance with Nasdaq Capital Market's minimum bid price requirement.
- Stock will begin trading on a post-split basis on April 24, 2026, under the existing ticker CUE with new CUSIP 22978P205.
- No fractional shares will be issued; shareholders will receive cash in lieu of fractional shares.
- The number of authorized shares and par value remain unchanged.
Financial Impact
The reverse stock split will increase the stock price by a factor of 30, with proportional adjustments to outstanding options, warrants, and equity plan shares. Exact cash payments for fractional shares depend on the pre-split closing price.
Risk Factors
- Reverse stock splits are often perceived negatively by the market as they can signal financial distress.
- The company disclosed a going concern determination in the filing, indicating insufficient capital to continue operations beyond the next twelve months.
- Potential delisting risk remains if the stock fails to sustain compliance with Nasdaq's continued listing standards.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-168907 |
| Document: cue-ex3_1.htm | 0001193125-26-168907 |
| Document: 0001193125-26-168907-index-headers.html | 0001193125-26-168907 |
| Document: 0001193125-26-168907-index.html | 0001193125-26-168907 |
| Document: 0001193125-26-168907.txt | 0001193125-26-168907 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 11d ago | Insider Cluster | $18.67 $16.71 | ▲ +10.50% | ▲ +9.39% | $18.66 (+0.05%) |
Oct 13, 2026 12d ago | 144 | $18.60 $18.67 | ▲ +0.38% | ▲ +0.09% | $18.66 (+0.32%) |
Oct 8, 2026 18d ago | SC 13G/A | $22.33 $27.66 | ▲ +23.87% | ▲ +23.27% | $18.66 (−16.44%) |
Sep 21, 2026 5w ago | 8-K | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.66 (−33.99%) |
Sep 20, 2026 5w ago | Press Release | $28.27 $30.90 | ▲ +9.30% | ▲ +9.32% | $18.66 (−33.99%) |
Aug 21, 2026 9w ago | EFFECT | $23.98 $23.18 | ▲ +3.34% | ▲ +3.04% | $18.66 (+22.19%) |
Aug 17, 2026 10w ago | Insider Cluster | $25.70 $26.28 | ▼ −2.26% | ▼ −2.05% | $18.66 (+27.39%) |
Aug 14, 2026 10w ago | Press Release | $27.64 $25.70 | ▼ −7.02% | ▼ −6.34% | $18.66 (−32.49%) |
Aug 13, 2026 10w ago | 144 | $34.20 $27.64 | ▼ −19.18% | ▼ −18.71% | $18.66 (−45.44%) |
Jul 9, 2026 15w ago | Press Release | $36.78 $30.92 | ▼ −15.93% | ▼ −15.17% | $18.66 (−49.27%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers